康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

未开盘 10-08 16:08:17

105.700

-3.400

-3.12%

最高111.500	最低104.900	成交量1,104万
今开110.900	昨收109.100	日振幅6.05%
总市值973.50亿	流通市值973.50亿	总股本9.21亿
成交额11.91亿	换手率1.20%	流通股本9.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":105.7,"timestamp":1791446897010,"preClose":109.1,"halted":0,"volume":11036193,"delay":0,"changeRate":-0.031164069660861517,"floatShares":921000000,"shares":921000000,"eps":-1.232771,"marketStatus":"未开盘","change":-3.4,"latestTime":"10-08 16:08:17","open":110.9,"high":111.5,"low":104.9,"amount":1191393735,"amplitude":0.060495,"askPrice":105.8,"askSize":2000,"bidPrice":105.6,"bidSize":32000,"shortable":3,"etf":0,"ttmEps":-1.220827,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791509400000},"marketStatusCode":0,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":109.1,"openAndCloseTimeList":[[1791423000000,1791432000000],[1791435600000,1791446400000]],"volumeRatio":1.844632,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.6563,"impliedVolPercentile":0.5618},"requestUrl":"/m/hq/s/09926/tweets","defaultTab":"tweets","newsList":[{"id":"1170679671","title":"异动解读｜康方生物盘中下跌3.02%，生物医药板块获利回吐拖累创新药个股","url":"https://stock-news.laohu8.com/highlight/detail?id=1170679671","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170679671?lang=zh_cn&edition=full","pubTime":"2026-10-08 13:51","pubTimestamp":1791438696,"startTime":"0","endTime":"0","summary":"10月8日，康方生物盘中下跌3.02%，报105.8港元，成交额8.69亿港元。消息面上，生物医药板块延续前一日调整态势，短线获利盘继续兑现收益，康方生物随板块承压。前一日恒生生物科技指数大跌3.15%，金斯瑞生物科技重挫逾14%，板块情绪显著转弱。康方生物作为创新药核心标的，此前受阿斯利康20亿美元战略投资Summit及依沃西单抗国际临床进展推动连续上涨，短期亦面临获利回吐。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康方生物随板块回调，创新药获利盘出逃","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145083319","title":"康方生物发布2026年9月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1145083319","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145083319?lang=zh_cn&edition=full","pubTime":"2026-10-07 17:36","pubTimestamp":1791365784,"startTime":"0","endTime":"0","summary":"康方生物科技（开曼）有限公司于2026年10月7日披露了截至2026年9月30日的股份变动月报。报告显示，公司法定注册股本依旧为5,000,000,000股普通股，面值USD 0.00001，总额维持USD 50,000，与上月底未发生变化。公告显示，公司于2026年9月末已发行股份为921,143,176股，无库存股份，合计已发行股份总数为921,143,176股，与上月底保持一致。截至2026年9月末，公司股本规模保持稳定。该公告由公司董事夏瑜签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157757634","title":"异动解读｜康方生物盘中下跌3.16%，生物医药板块大幅回调拖累创新药个股","url":"https://stock-news.laohu8.com/highlight/detail?id=1157757634","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157757634?lang=zh_cn&edition=full","pubTime":"2026-10-07 09:46","pubTimestamp":1791337619,"startTime":"0","endTime":"0","summary":"10月7日，康方生物盘中下跌3.16%，报107.1港元，成交额8448.17万港元。消息面上，整个生物医药板块出现大幅回调，恒生生物科技指数跌3.15%，恒生医疗保健指数跌2.73%，万得港股中国创新药指数跌2.39%，板块系统性回调对个股形成明显拖累。然而在经历连续上涨后，板块于10月7日出现集中获利回吐，金斯瑞生物科技跌14.81%，再鼎医药跌4.47%，康方生物亦随板块下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"生物医药板块回调，康方生物随势走低","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673064659","title":"生物医药板块大幅回调 恒生生物科技指数跌3.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673064659","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673064659?lang=zh_cn&edition=full","pubTime":"2026-10-07 09:35","pubTimestamp":1791336927,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块大幅回调，截至发稿，恒生生物科技指数跌3.15%，恒生医疗保健指数跌2.73%，万得港股中国创新药指数跌2.39%。个股方面，金斯瑞生物科技（01548）跌14.81%，再鼎医药（09688）跌4.47%，药明合联（02268）跌3.68%，药明生物（02269）跌2.50%，百济神州（06160）跌1.18%，诺诚健华（09969）跌1.43%，康诺亚-B（02162）跌1.32%，康方生物（09926）跌1.45%。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993174","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518857.USD","LU0856984785.SGD","IE00B543WZ88.USD","BK1161","02162","LU0348825331.USD","LU1720050803.USD","BK4588","09969","09926","IE00B0JY6N72.USD","LU0228659784.USD","LU0211977185.USD","LU0561508036.HKD","XBI","09688","SG9999002463.SGD","06160","LU0320764243.SGD","LU0348766576.USD","LU0516423174.USD","LU2039709279.SGD","SG9999014674.SGD","161726","LU0572944931.SGD","LU2488822045.USD","KURE","LU0348784397.USD","399441","LU0320764599.SGD","LU1242518931.SGD","LU3063872942.SGD","BK1521","LU0417516738.SGD","LU0828237510.HKD","LU0456846285.SGD","LU1880383366.USD","LU0359202008.SGD","LU0244354667.USD","LU0588546209.SGD","SG9999002562.SGD","01548","LU0052750758.USD","02268","02269","BK1574","LU0456827905.SGD","BK1141","LU1794554557.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673058257","title":"【热门行业】光遗传学获2026年诺奖：产业仍处早期，眼科赛道临床进度领先（附相关标的）","url":"https://stock-news.laohu8.com/highlight/detail?id=2673058257","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673058257?lang=zh_cn&edition=full","pubTime":"2026-10-06 18:22","pubTimestamp":1791282120,"startTime":"0","endTime":"0","summary":"诺奖落地的消息引发市场对光遗传学、脑科学相关赛道的关注。从行业发展阶段来看，光遗传学整体仍处于产业化早期，基础科研仍是核心需求，临床商业化尚未全面兑现。下游临床应用端，眼科赛道临床进度相对领先，但全行业目前尚无光遗传学产品完成全流程审批并获批上市，从临床试验到产品上市仍存在重大不确定性。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/YWU1MjY3ODMwOTg1Nzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YWU1MjY3ODMwOTg1Nzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993152","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1688375341.USD","LU0359202008.SGD","LU0516423174.USD","HK0000320264.USD","LU0181495838.USD","HK0000306685.HKD","LU0417516902.SGD","LU0823426308.USD","LU1242518931.SGD","BK1576","BK1161","LU0348767384.USD","LU0979878070.USD","BK1191","LU0456827905.SGD","LU0140636845.USD","LU0572944931.SGD","09688","LU1961090484.USD","BK1588","LU0052750758.USD","LU0708995583.HKD","09969","01548","IBBQ","LU0051755006.USD","LU0708995153.HKD","LU0211977185.USD","IE00B0JY6N72.USD","LU0516422440.USD","09926","LU0043850808.USD","01477","LU0128522744.USD","LU0516423091.SGD","LU0819121731.USD","LU0029874905.USD","LU0456846285.SGD","01952","LU0307460666.USD","02269","LU0540923850.HKD","BK1574","LU1794554557.SGD","KURE","LU0359201612.USD","LU1720050803.USD","LU0634319403.HKD","02228","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673803803","title":"港股异动 | 创新药概念股涨势延续 美银指近期三项重磅合作强化板块动能 ESMO有望带来密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2673803803","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673803803?lang=zh_cn&edition=full","pubTime":"2026-10-06 10:05","pubTimestamp":1791252333,"startTime":"0","endTime":"0","summary":"美银证券发布研报称，中国医药/生物科技近期三项合作强化板块动能渤海证券表示，近期AI制药催化密集，行业焦点逐步从模型能力转向湿实验验证效率等方面，建议关注AI制药相关基因合成、蛋白表达、试剂耗材、动物模型及临床试验等细分赛道的投资机遇。同时，2026年ESMO年会即将召开，优异临床数据有望读出，带来板块密集催化，建议关注创新药、CXO及生命科学上游产业链等的投资机遇。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1589","LU2476274308.USD","IBBQ","LU2476274720.SGD","01177","LU2488822045.USD","LU1720050803.USD","LU0561508036.HKD","LU0348825331.USD","LU0348766576.USD","BK1161","06978","MEDX","159992","KURE","LU0348735423.USD","LU1794554557.SGD","IE00BZ08YT58.USD","KCAI","LU0417516902.SGD","LU0348767384.USD","IE00B543WZ88.USD","BK4585","LU2778985437.USD","LU0417516571.SGD","09926","IE00BZ08YS42.EUR","LNGR","IE00B5MMRT66.SGD","HK0000165453.HKD","BK1515","LU0417516738.SGD","LU1961090484.USD","LU0348783233.USD","IE00BPRC5H50.USD","01672","BK1574","LU2399975544.HKD","BK1521","BK4588","LU0540923850.HKD","LU0634319403.HKD","06185","IE00BZ08YR35.GBP","LU0348784397.USD","LU0348827113.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673033818","title":"生物医药板块走高 恒生生物科技指数涨2.32% 金斯瑞生物科技（01548）涨5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673033818","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673033818?lang=zh_cn&edition=full","pubTime":"2026-10-06 10:01","pubTimestamp":1791252073,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块走高，恒生生物科技指数涨2.32%，恒生医疗保健指数涨2.19%，万得中国创新药指数涨2.15%。个股方面，再鼎医药涨6.97%，金斯瑞生物科技涨5.30%，君实生物涨3.07%，药明生物涨3.07%，康方生物涨2.92%，康诺亚-B涨2.33%，泰格医药涨1.90%，诺诚健华涨1.87%。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MGY1NDA5NTM4NDQ4Mw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGY1NDA5NTM4NDQ4Mw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993104","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","LU1880383366.USD","02269","09926","LU0051755006.USD","LU1242518857.USD","LU0348735423.USD","LU0634319403.HKD","LU0708995583.HKD","KURE","LU2488822045.USD","HK0000306701.USD","SG9999002562.SGD","BK1515","HK0000320223.HKD","03347","LU0359202008.SGD","BK1574","LU0140636845.USD","LU0039217434.USD","161726","LU0348784397.USD","LU0307460666.USD","LU0561508036.HKD","09688","LU0516422952.EUR","LU0417516902.SGD","LU0708995153.HKD","XBI","LU0456827905.SGD","09969","LU0181495838.USD","LU0320764599.SGD","IE00BPRC5H50.USD","LU1794554557.SGD","01548","02162","LU2778985437.USD","BK1141","LU0516423174.USD","SG9999002463.SGD","IE00B543WZ88.USD","BK4581","LU1720050803.USD","LU0052750758.USD","LU2039709279.SGD","399441","LU0128522744.USD","LU0327786744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673734038","title":"创新药概念普升 歌礼制药-B（01672）涨11.78%、再鼎医药（09688）涨6.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673734038","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673734038?lang=zh_cn&edition=full","pubTime":"2026-10-06 09:54","pubTimestamp":1791251688,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念普涨，截至发稿，歌礼制药-B 涨11.78%，再鼎医药涨6.55%，金斯瑞生物科技涨5.30%，晶泰控股涨4.40%，中国生物制药涨3.96%，三生制药涨3.41%，药明生物涨3.16%，康方生物涨3.11%，云顶新耀涨3.10%，四环医药涨2.82%。2026ESMO已公布LBA标题，29项LBA的试验药物由中国药企原研或参与开发，涉及约20家企业，其中5项进入主席研讨会。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993103","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","00460","09688","LU2778985437.USD","MEDX","01672","ZLAB","01548","01952","LU2476274308.USD","02228","BK1521","IE00BZ08YT58.USD","LU0359201612.USD","LU0211977185.USD","LU0516422366.SGD","LU0029874061.USD","KURE","IE00BPRC5H50.USD","IBBQ","LU0029874905.USD","LU0348784397.USD","LU0052750758.USD","09926","LU1242518931.SGD","01177","06978","LU0823426308.USD","BK1161","BK4139","01530","LNGR","LU0320764599.SGD","LU0516423091.SGD","159992","BK1515","LU0320764243.SGD","LU0708995153.HKD","02269","LU0348735423.USD","LU0140636845.USD","BK1141","LU0348766576.USD","LU0417516902.SGD","SG9999002463.SGD","BK1191","BK4588","BK1574","HK0000306701.USD","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110507209","title":"异动解读｜康方生物盘中上涨3.3%，依沃西联合疗法国际临床开发取得新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1110507209","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110507209?lang=zh_cn&edition=full","pubTime":"2026-10-06 09:43","pubTimestamp":1791251024,"startTime":"0","endTime":"0","summary":"10月6日，康方生物盘中向上异动3.3%，报109.5港元，成交额4432.28万元。催化事件来自公司最新研发动态：海外合作伙伴与阿斯利康、第一三共正式达成依沃西与TROP2 ADC的全球联合开发合作协议，将率先启动一线三阴性乳腺癌国际多中心III期临床研究，加速该双抗在肺癌、乳腺癌等重大实体瘤领域的全球布局。康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康方生物异动上涨，依沃西联合疗法获全球开发新进展","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673792787","title":"【券商聚焦】国金证券：行业有望迎业绩与估值戴维斯双击，创新药板块底部配置价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2673792787","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673792787?lang=zh_cn&edition=full","pubTime":"2026-10-05 08:50","pubTimestamp":1791161445,"startTime":"0","endTime":"0","summary":"随着后续管线商业化兑现、全球创新价值链话语权提升，行业有望迎来业绩与估值的戴维斯双击，创新药板块底部配置价值凸显。中国研究占全体大会核心LBA总量的1/3，这标志着中国肿瘤创新研发已深度融入全球研发体系，成为驱动全球肿瘤诊疗升级的重要力量，持续利好国内创新药企国际化发展与临床价值兑现。2026 ESMO已公布LBA标题，29项LBA的试验药物由中国药企原研或参与开发，涉及约20家企业，其中5项进入主席研讨会。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992996","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","LU1242518931.SGD","01801","MEDX","01177","06160","LU0211977185.USD","09688","02616","LU0244354667.USD","LU0856984785.SGD","BK1576","06978","IE0008368742.USD","LU2399975544.HKD","BK1515","LU1794554557.SGD","LU1328277881.USD","BK0201","LU0455707207.USD","HK0000165453.HKD","LU0823426308.USD","LU1226287875.USD","LU0052750758.USD","IE00BPRC5H50.USD","LU1226288253.USD","09995","600109","BK1583","LU2242644610.SGD","159992","KCE","LNGR","BK1610","LU0359202008.SGD","IBBQ","LU0823426480.USD","LU0043850808.USD","LU1807302812.USD","LU0315179316.USD","01877","LU0540923850.HKD","09926","KURE","01093","06185","LU0314109678.HKD","LU0516422952.EUR","02142","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673794647","title":"【特约大V】郭家耀：外围加息预期稍为降温，有利大市跌势暂时喘定","url":"https://stock-news.laohu8.com/highlight/detail?id=2673794647","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673794647?lang=zh_cn&edition=full","pubTime":"2026-10-05 08:34","pubTimestamp":1791160467,"startTime":"0","endTime":"0","summary":"外围加息预期稍为降温，有利大市跌势暂时喘定，但长期利率持续上升，不利股市发展，预料指数或进一步考验23,500点支持，上方阻力则在24,500点附近。日前阿斯利康斥资20亿美元战略入股Summit，进一步凸显依沃西的价值。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/NmQyMzI4NWZmMGRlNDRmMTg4YmIyOTUwMDI3OTAzODMzODA5NjYxNDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmQyMzI4NWZmMGRlNDRmMTg4YmIyOTUwMDI3OTAzODMzODA5NjYxNDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992994","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","LU2488822045.USD","LU2778985437.USD","LU0417516571.SGD","LU0561508036.HKD","LU1794554557.SGD","LU0634319403.HKD","LU1961090484.USD","TMF","US2Y.BOND","US10Y.BOND","LU0348784397.USD","LU0348767384.USD","KURE","LU0348783233.USD","TLT","LU2399975544.HKD","BK1161","LU0348766576.USD","LU0348827113.USD","US30Y.BOND","LU2476274308.USD","LU0417516902.SGD","LU0540923850.HKD","09926","LU0417516738.SGD","LU1720050803.USD","TLTW","IE00B5MMRT66.SGD","US7Y.BOND","IE00BPRC5H50.USD","US5Y.BOND","IE00B543WZ88.USD","LU2476274720.SGD","US6M.BOND","LU0348825331.USD","BK1574","US3Y.BOND","US12M.BOND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154327445","title":"异动解读｜康方生物盘中下跌3.59%，阿斯利康投资驱动连续大涨后获利盘回吐叠加板块普跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1154327445","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154327445?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:51","pubTimestamp":1790905867,"startTime":"0","endTime":"0","summary":"10月2日，康方生物盘中下跌3.59%，报103.8港元，成交额1.34亿港元。此前受阿斯利康20亿美元战略入股海外合作伙伴Summit Therapeutics消息提振，康方生物9月29日大涨15.54%，9月30日续涨2.26%，短期累计涨幅显著，获利资金存在兑现压力。该交易核心标的为康方生物研发的依沃西单抗，阿斯利康以每股18.36美元认购Summit可转换优先股，并围绕依沃西与其ADC管线展开联合临床合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"阿斯利康入股利好兑现，康方生物冲高回落","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150891463","title":"康方生物2026年中期财报：营收18.06亿元，净亏损4.47亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1150891463","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150891463?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:07","pubTimestamp":1790759263,"startTime":"0","endTime":"0","summary":"2026年上半年，康方生物实现总营收18.06亿元，同比增长27.92%。报告期内，商业销售收入为18.03亿元，同比增长28.65%，商业授权收入为2.5百万元。期内公司净亏损4.47亿元，较上年同期的5.88亿元减亏1.41亿元。管理层表示，亏损减少主要得益于销售收入增长以及部分投资损失计提的减少。根据财报显示，净亏损规模及相应占收入比率均有所下降。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康方生物2026年中期财报：营收18.06亿元，净亏损4.47亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671740762","title":"投行下调预期，阿斯利康20亿美元押注伊沃西：康方生物再冲千亿市值","url":"https://stock-news.laohu8.com/highlight/detail?id=2671740762","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671740762?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:15","pubTimestamp":1790756100,"startTime":"0","endTime":"0","summary":"9月28日，阿斯利康（AZN）宣布以20亿美元认购SummitTherapeutics（SMMT）的可转换优先股，并围绕后者自康方生物（09926）授权引进的PD-1/VEGF双抗依沃西达成临床合作安排。消息公布后投资者反应积极。康方生物9月29日涨15.54%，收报106.3港元，成交额34.78亿港元，较前一交易日的7.31亿港元明显增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609303887728064.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609303887728064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1961090484.USD","09926","LU0348735423.USD","LU0634319403.HKD","KURE","LU2488822045.USD","BK1574","IE00B5MMRT66.SGD","LU0348783233.USD","LU0348784397.USD","LU0561508036.HKD","LU0348766576.USD","LU0417516902.SGD","LU2476274308.USD","IE00BPRC5H50.USD","LU1794554557.SGD","LU0348825331.USD","LU0417516571.SGD","LU2778985437.USD","LU0417516738.SGD","BK1161","LU2476274720.SGD","IE00B543WZ88.USD","LU0348767384.USD","LU1720050803.USD","LU2399975544.HKD","LU0348827113.USD","LU0540923850.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671275483","title":"野村：予康方生物(09926)目标价138.29港元以及“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2671275483","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671275483?lang=zh_cn&edition=full","pubTime":"2026-09-30 14:32","pubTimestamp":1790749960,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，野村发布研报称，予康方生物目标价138.29港元以及“买入”评级。野村表示，9月29日港股开盘前，康方生物及其海外合作伙伴Summit Therapeutics宣布，Summit获得阿斯利康20亿美元的战略投资。阿斯利康对Summit可转换优先股的这笔20亿美元投资相当于Summit普通股约12%的股权。该行认为，这对与依沃西单抗在全球市场的开发是利好消息，而依沃西单抗正是康方生物核心价值的组成部分。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671027548","title":"大和：康方生物(09926)全球伙伴Summit获阿斯利康投资 提升依沃西全球高峰销售潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2671027548","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671027548?lang=zh_cn&edition=full","pubTime":"2026-09-30 14:30","pubTimestamp":1790749814,"startTime":"0","endTime":"0","summary":"大和指出，评估sonesitatug vedotin与依沃西联合用于胃肠道癌的临床研究即将展开，双方将共同分担相关研究费用；Summit与阿斯利康亦拟评估依沃西与阿斯利康其他抗癌药物的联合方案。该行指出，Summit此前全球仅进行一项消化道适应症试验，即结直肠癌试验，市场对依沃西在消化道癌的预期原本有限。在阿斯利康强而有力的策略投资，以及sonesitatug vedotin在消化道癌具潜在同类最佳潜力的情况下，依沃西全球消化道癌前景改善，最终有望提升其全球高峰销售潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"大和：康方生物(09926)全球伙伴Summit获阿斯利康投资 提升依沃西全球高峰销售潜力","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274308.USD","LU2476274720.SGD","LU2488822045.USD","LU1720050803.USD","LU0561508036.HKD","LU0348825331.USD","LU0348766576.USD","BK1161","KURE","LU0348735423.USD","LU1794554557.SGD","LU0417516902.SGD","LU0348767384.USD","IE00B543WZ88.USD","LU2778985437.USD","LU0417516571.SGD","09926","IE00B5MMRT66.SGD","LU0417516738.SGD","LU1961090484.USD","LU0348783233.USD","IE00BPRC5H50.USD","BK1574","LU2399975544.HKD","LU0540923850.HKD","LU0634319403.HKD","LU0348784397.USD","LU0348827113.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168683959","title":"异动解读｜康方生物盘中下跌3.86%，前日大涨逾15%后获利盘回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1168683959","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168683959?lang=zh_cn&edition=full","pubTime":"2026-09-30 09:31","pubTimestamp":1790731881,"startTime":"0","endTime":"0","summary":"9月30日，康方生物盘中下跌3.86%，报102.4港元，成交额1.3亿港元。消息面上，康方生物前一交易日因阿斯利康20亿美元战略入股其海外合作伙伴Summit Therapeutics大涨15.54%，收报106.3港元，单日市值增逾130亿港元。该交易核心标的为康方生物研发的依沃西单抗——全球首个PD-1/VEGF双特异性抗体。此外，南向资金前一交易日对康方生物有所减持，亦反映部分资金选择在高位兑现收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康方生物获利盘回吐，聚焦依沃西审批进展","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174511728","title":"康方生物：李百勇被动摊薄，好仓比例降至5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174511728","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174511728?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:33","pubTimestamp":1790674409,"startTime":"0","endTime":"0","summary":"李百勇因康方生物（09926）于2025年9月4日完成配售23,550,000股新股，其好仓持股数目不变（持股数目仍为5042.32万股）。该配售属公司增发股份，并非在联交所公开市场直接买卖，属于被动摊薄。李百勇此次被动摊薄前持有康方生物好仓5042.32万股，占比5.62%；持股数目不变，因康方生物增发新股，好仓比例由5.62%被动降至5.47%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126779753","title":"康方生物：夏瑜增持，好仓比例升至25.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126779753","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126779753?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:32","pubTimestamp":1790674346,"startTime":"0","endTime":"0","summary":"夏瑜于2026年6月15日在联交所场内以每股均价94.0665港元买入康方生物10万股，涉资约940.66万港元，属场内主动交易，即在二级市场直接买卖股份。夏瑜此次增持前持有康方生物好仓2.30亿股（比例24.99%），增持后持股量为2.30亿股，好仓比例升至25.0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671293354","title":"创新药概念股逆市走强 康方生物（09926）涨16.85%、康诺亚-B（02162）涨10.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671293354","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671293354?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:20","pubTimestamp":1790659249,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股逆市走强，康方生物 涨16.85%，康诺亚-B涨10.32%，乐普生物涨7.88%，荣昌生物涨5.41%，科伦博泰生物涨5.32%，博安生物涨4.74%，恒瑞医药涨4.02%，再鼎医药涨4.02%。根据Insight数据，除已经在美国获批上市的药物外，已达成出海合作的国产创新药中有27款处于临床后期。其中，依沃西单抗、匹米替尼已在美国申请上市，芦康沙妥珠单抗、伦康依隆妥单抗、SSGJ-707等重点品种处于临床III期。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992749","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348767384.USD","BK1588","02157","LU2488822045.USD","LU0348827113.USD","LU0561508036.HKD","LU2476274308.USD","LU0417516738.SGD","LU2778985437.USD","LU0196878994.USD","LU1961090484.USD","IE00BPRC5H50.USD","LU0634319403.HKD","09926","BK1587","LU0359201612.USD","09995","LU1720050803.USD","LU0359202008.SGD","BK1583","LU0348784397.USD","BK1161","LU0359201885.HKD","BK1191","KURE","LU0417516571.SGD","LU2328871848.SGD","IE00B5MMRT66.SGD","LU1023057109.AUD","LU0348783233.USD","MEDX","06990","09688","LU0348766576.USD","LU1794554557.SGD","IBBQ","BK1574","06955","159992","IE00B543WZ88.USD","LU0348825331.USD","LU1969619763.USD","LU2543165471.USD","02162","01276","06978","LU0348735423.USD","LNGR","LU2476274720.SGD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.0276},{"period":"1month","weight":0.0988},{"period":"3month","weight":0.0869},{"period":"6month","weight":-0.2352},{"period":"1year","weight":-0.2546},{"period":"ytd","weight":-0.0646}],"compareEarnings":[{"period":"1week","weight":-0.0336},{"period":"1month","weight":-0.0605},{"period":"3month","weight":-0.0161},{"period":"6month","weight":-0.0814},{"period":"1year","weight":-0.1134},{"period":"ytd","weight":-0.072}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼（卡度尼利，PD-1/CTLA-4）、依达方（依沃西，PD-1/VEGF）、莱法利（AK117，CD47）、普络西（AK109，VEGFR-2）、安尼可（派安普利，PD-1）、科泰莱（塔戈利单抗，PD-L1）和用于代谢及自免领域的伊喜宁（伊努西单抗，PCSK9）、爱达罗（依若奇单抗，IL-12/IL-23）、古莫奇单抗（AK111，IL-17）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.021305},{"month":6,"riseRate":0.571429,"avgChangeRate":0.077852},{"month":7,"riseRate":0.571429,"avgChangeRate":0.084887},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.012805},{"month":9,"riseRate":0.571429,"avgChangeRate":0.060911},{"month":10,"riseRate":0.428571,"avgChangeRate":0.035511},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}